

Frequently Asked Questions

Glycemic Management - Adult Policy

Table of contents

Table of contents.....	1
Contact	4
Policy Information.....	5
Why were the provincial glycemic management policy and procedures for hypoglycemia management and hyperglycemia management developed?	5
Who created these governance documents?	6
Where can I learn more about the definitions used in the policy suite and governance documents?.....	6
I work for Covenant Health, do these resources apply me?	6
Glycemic Management Policy Suite.....	7
Who does the policy suite apply to?.....	7
What are the blood glucose (BG) targets for adult patients in hospital?	7
Why do health care professionals need to use the AHS point of care testing (POCT) Blood Glucose (BG) meter?	8
What is the difference between a capillary blood glucose (CBG) meter and an interstitial continuous glucose monitor (CGM)?	9
What is the difference between a blood glucose (BG) result and an interstitial glucose result?	10
Is there a resource I can use to share information with patients about why AHS staff need to use the AHS blood glucose (BG) meter while patients are in hospital?	10
Can my patient use their own lancing device to obtain a capillary blood glucose sample?	11
My patient has refused blood glucose (BG) testing with the POCT AHS BG meter. Where do I document their reported glucose result?	11
For Connect Care sites, what do I scan to ensure the AHS BG meter result is accurately uploaded to the patient's chart?	12

When should blood glucose (BG) testing occur?	12
When should blood glucose (BG) test be repeated?	12
What is the recommended timing of insulin administration?	12
What is Basal Bolus Insulin Therapy (BBIT)?	13
What is meal insulin?.....	13
What is the difference between rapid acting insulin and short acting insulin?.....	14
When should insulin be held?.....	14
Where do I find the guidelines for Safe Management of Insulin Pump Therapy (IPT) in hospital?.....	14
Hypoglycemia Procedure.....	15
Who does the hypoglycemia procedure apply to?	15
What are the signs and symptoms of hypoglycemia?.....	15
Why do some patients experience asymptomatic hypoglycemia or hypoglycemia unawareness?	16
Should the meal/bolus insulin be held if the patient's pre-meal blood glucose (BG) is less than 4.0mmol/L?	16
When should 15 grams carbohydrate be given orally to a patient?	16
What are some examples of 15 grams of carbohydrate that can be given orally?.....	17
When a conscious patient has a tube feed, how do I treat the hypoglycemia?.....	17
Where do I find information on alternate/replacement food menu items when the food or menu item recommended in the procedure is not available on my unit or not appropriate for the patient?	18
What is a schedule 1 medication?.....	18
Can nurses (RN, RPN, LPN) give D50W without a prescriber's order?	18
What if nurses on our unit are not competent and confident to administer IV direct medications?.....	19
Why is a large vein required for the administration of D50W?.....	19
Can I give D50W IV after I administer glucagon (inhaled) if an IV is established or do I wait for 15 minutes?	19
Where can I find information on how to administer glucagon?	20

Why is there a switch from subcutaneously or intramuscularly (SC or IM) glucagon to intranasal glucagon on the formulary?	20
Do I need an order to administer glucagon in an emergent situation?	20
What do I do for patients with a blood glucose (BG) between 4.0 - 5.0 mmol/L?	20
Why shouldn't the patient be sent off the unit when their blood glucose (BG) is less than 4.0mmol/L?	21
What is the rationale for re-assessing the blood glucose (BG) one hour after treatment of hypoglycemia?	21
The hypoglycemia procedure is very lengthy. How can nurses respond in a timely manner in a crisis situation?	21
How can I document the elements of the hypoglycemia procedure in a timely fashion?	22
Hyperglycemia Procedure	23
Why shouldn't the patient with diabetes be sent off the unit if their blood glucose (BG) is greater than 18.0mmol/L?	23
What is Diabetic Ketoacidosis (DKA)?	23
What is Hyperosmolar Hyperglycemic State (HHS)?	24
How are ketones tested?	24
What are SGLT2 inhibitor medications?	24
Where can nurses find a quick reference for treatment and management of hyperglycemia?	25
General Information	26
What is the difference between Type 1, Type 3c and Type 2 diabetes?	26
In what aspects are the management of Type 1, Type 3c and Type 2 diabetes similar? ..	28
Where can I find additional resources supporting improved glycemic management in hospital?	28
2024 Revision Highlights	29
What are the updates to the policy and procedures in Fall 2024?	29
Resources and References:	33
AHS Resources:	33
Non-Alberta Health Services Documents:	33
Appendix A: Glycemic Management - Adult Policy Working Group	34

© 2024 Alberta Health Services



This work is licensed under a Creative Commons Attribution Non-commercial-Share Alike 4.0 International license. To view a copy of this licence, see <https://creativecommons.org/licenses/by-nc-sa/4.0/>. You are free to copy, distribute and adapt the work for non-commercial purposes, as long as you attribute the work to Alberta Health Services (AHS) and abide by the other licence terms. If you alter, transform, or build upon this work, you may distribute the resulting work only under the same, similar, or compatible licence. The licence does not apply to AHS trademarks, logos or content for which AHS is not the copyright owner.

This material is intended for general information only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, AHS does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. AHS expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.

Contact

For more information, please contact:
policy@ahs.ca

practice.consultation@ahs.ca

Policy Information

Why were the provincial glycemic management policy and procedures for hypoglycemia management and hyperglycemia management developed?

These documents were developed to support improved glycemic management for adult patients in hospital, through the identification of strategies to help patients achieve their identified glucose targets in hospital.

Literature suggests that patients with diabetes experience hyperglycemia (high blood glucose) 38 per cent of the time they are in hospital. Hyperglycemia increases the risk of complications including: post-operative infections, pneumonia, diabetic ketoacidosis (DKA), and delayed wound healing. Improving blood glucose (BG) control in hospital has been associated with shorter length of stay in hospital and decreased rates of readmission. National guidelines recommend BG targets of **5.0-10.0 mmol/L** for most patients with diabetes in hospital.

The three documents aim to improve adult glycemic management in AHS acute care inpatient settings, through a series of coordinated strategies which include:

- Establishing an acceptable BG targets for adults (5.0-10.0 mmol/L for most patients, see FAQ page 7 for exceptions)
- Recommending BG testing regimens for adults in hospital
- Identifying basal bolus insulin therapy as the most appropriate treatment regimen for adults requiring subcutaneous insulin
- Supporting the safe management of insulin pump therapy in hospital when appropriate
- Early recognition and treatment of hypoglycemic and hyperglycemic events
- Supporting the review of hypoglycemic and hyperglycemic events so as to implement appropriate interventions to achieve recommended BG targets
- Identifying the potential safety concerns of using home glucose monitoring devices and encouraging communication and education to prevent safety concerns

Who created these governance documents?

These documents have been developed by a provincial multidisciplinary working group with Nursing, Pharmacy, Allied Health, Dietitian, Physician, Policy and Administration representatives from across five zones, and in consultation with Health Professions Strategy and Practice, College of Registered Nurses of Alberta (CRNA) and College of Licensed Practical Nurses of Alberta (CLPNA). See [Appendix A](#) for working group membership.

Where can I learn more about the definitions used in the policy suite and governance documents?

AHS policy services (Insite) provides direction, framework and resources to develop provincial governance documents. You can reach out to policy@ahs.ca for more information.

I work for Covenant Health, do these resources apply me?

Yes, this resource and others listed on the provincial policy resource webpage are available to support the policy suite. Covenant Health employees and clinicians should refer to the Covenant Health governance documents for specific clinical guidance. AHS and Covenant Health clinicians and employees participated in the development of these documents.

Glycemic Management Policy Suite

Who does the policy suite apply to?

This policy suite applies to the adult in-patient settings in any AHS acute care setting, including intensive care units, emergency departments, urgent care centres, day wards, and Addiction and Mental Health inpatient settings.

These documents may also be used in non-acute care settings; however, the site/unit managers are responsible for determining whether the governance documents in whole or in part are appropriate to their patient care setting and communicating that out to staff.

What are the blood glucose (BG) targets for adult patients in hospital?

Diabetes Canada Clinical Practice Guidelines recommends (BG) targets of **5.0-10.0 mmol/L** for most hospitalized patients. These targets are higher and more liberal than the typical targets for patients with diabetes who are treated in the outpatient setting.

Higher values **5.0-12.0 mmol/L** are acceptable for:

- The frail elderly and those with dementia: *an older adult and/or with dementia assessed as physically and/or cognitively frail at risk for confusion, agitation or falls*
- Patients with limited life expectancy
- Patients at risk for severe hypoglycemia (e.g. hypoglycemia unawareness)

In critically ill patients the target BG range is **6.0-10.0 mmol/L**, with the exception for those patients with acute coronary syndrome where their BG targets are 7.0-10.0 mmol/L.

For patients with diabetes in pregnancy the target BG range is:

Antepartum:

- fasting and pre-prandial: 3.8–5.2 mmol/L; and
- one (1) hour post-prandial: below 7.8 mmol/L; and
- two (2) hours post prandial: below 6.7 mmol/L; or
- individualized targets determined by the most responsible healthcare practitioner (MRHP).

During active labour:

- BG targets are 4.0–7.0 mmol/L.

For more information, please see [Diabetes Canada | Clinical Practice Guidelines](#)

Why do health care professionals need to use the AHS point of care testing (POCT) Blood Glucose (BG) meter?

The AHS point of care testing (POCT) blood glucose (BG) meter (e.g. Roche Inform II) undergoes daily quality assurance. AHS staff receive education and training to remain competent in the use of the AHS approved BG meter(s). The AHS POCT BG meter device is approved by Health Canada for in hospital use and meets accreditation standards for POCT BG reporting.

There are many factors that may impact the accuracy of home glucose monitors. Home glucose monitors may include Continuous Glucose Monitors (CGM) and capillary blood glucose (CBG) monitors. Results from CGM interstitial (sensor) readings and home BG meter test strips may be inaccurate in the hospital setting for a variety of reasons including expired supplies. Conditions common to the hospital population may affect sensor readings such as real time Continuous Glucose Monitor (rtCGM) or intermittently scanned Continuous Glucose Monitor (isCGM), rendering them inaccurate. These include:

- Low blood pressure, poor tissue perfusion, hydration status, edema
- Rapidly changing BG: interstitial fluid glucose levels may not accurately reflect BG levels leading to delayed detection of low or high BG
- Interference from medications and substances (e.g., acetaminophen, heparin, salicylic acid, dopamine, uric acid, ascorbic acid, maltose, hydroxyurea and mannitol; tissue deposits)
- Sensor positioning (e.g. incorrect insertion, sensor falling out, application of pressure over sensor)

CGM sensors may need to be removed prior to an imaging test such as an MRI. If sensors are left in place, confirm the sensor is reading accurately with a fingertip capillary blood glucose test after the exam or anytime the sensor reading does not display a glucose value reading that matches how the individual is feeling. Diagnostic Imaging staff will provide guidance to the individual using CGM devices if the sensor

has to be removed. Please see MyHealth Alberta patient resource: [continuous-glucose-monitors-imaging-tests-2023.pdf](#)

Home glucose monitoring technology is emerging and evolving to better support patients with diabetes in their glycemic management. Patients that want to continue the use of their home device in hospital, for their own information, should be encouraged to do so; however, these results should not be used to make treatment decisions such as administration of insulin or treatment of hypoglycemia. Patient-reported self-monitored glucose values and trends from a home glucose monitoring device should be reviewed and discussed with the multidisciplinary health care team, in conjunction with the in-hospital POCT BG values, where appropriate.



For sites using Connect Care, patients may share the glucose data obtained from their home device in a MyAHSCConnect flowsheet during a hospital admission. To activate this functionality in MyAHSCConnect, a prescriber must place a *MyChart IP Glucose Recording order*. Data documented in the MyAHSCConnect flowsheet will automatically transfer to the Connect Care inpatient chart and is viewable on the Glucose Management Accordion Report, found in the summary activity. If the patient is unable to record their values in MyAHSCConnect themselves, the health care provider is able to document patient reported readings on the *Inpatient Vital Signs flowsheet* activity under Point of Care Tests → Patient Reported Glucose row, which appears once the *MyChart IP Glucose Recording order* is placed. Refer to the *Inpatient Nurse - Glycemic Management Quick Start Guide* found on Insite or the Learning Home Dashboard.

What is the difference between a capillary blood glucose (CBG) meter and an interstitial continuous glucose monitor (CGM)?

A capillary blood glucose meter uses a small amount of capillary blood to provide a blood glucose result for the point in time collected.

A real time Continuous Glucose Meter (rtCGM) or intermittently scanned Continuous Glucose Meter (isCGM) provides an interstitial glucose result. These devices support

patients living with diabetes in reviewing trends in glucose patterns (sensor glucose results) to better manage their day-to-day glycemic needs.




What is the difference between a blood glucose (BG) result and an interstitial glucose result?

A BG result is a measurement of the glucose in the blood vessel or capillary.

An interstitial glucose result is a measurement of glucose from the interstitial fluid. Interstitial fluid surrounds the cells of your tissue below the skin.

Typically, glucose moves from the blood vessels and capillaries first and then into interstitial fluid. A blood glucose and interstitial (or sensor) glucose result are often not the same. A lag time may occur, especially when glucose values are changing quickly (e.g., after a meal is eaten or bolus of insulin administered). Blood glucose will rise and fall before interstitial glucose.



It is important to check a *blood glucose* before initiating treatment for hypoglycemia or hyperglycemia.

Is there a resource I can use to share information with patients about why AHS staff need to use the AHS blood glucose (BG) meter while patients are in hospital?

On MyHealth Alberta you can find the patient handout:

[Checking your blood glucose \(sugar\) level while you're in the hospital \(alberta.ca\)](http://alberta.ca)

This resource is available on the Glycemic Management Policy resource page.
[Glycemic Management Policy Suite | Alberta Health Services](#)

Can my patient use their own lancing device to obtain a capillary blood glucose sample?

For patients/families who prefer to use their home lancing device to obtain a capillary blood (fingertip) sample, home lancing devices and lancets can be used if the patient can provide their own supplies and are able to change and dispose of their lancet independently. When AHS staff are collecting the blood sample, staff are required to use the Workplace Health & Safety (WHS) approved safety lancet. An order is not required for a patient to use their own lancing device.

My patient has refused blood glucose (BG) testing with the POCT AHS BG meter. Where do I document their reported glucose result?

The health care team needs to know the source of the glucose result (blood glucose or interstitial glucose). When documenting a patient reported glucose reading, both the patient reported glucose value and the type of device must be indicated on the blood glucose record and insulin administration record.

In Connect Care, patients may share the glucose data obtained from their home device in a MyAHSCoconnect flowsheet during a hospital admission. To activate this functionality in MyAHSCoconnect, a prescriber must place a *MyChart IP Glucose Recording order*. Data documented in the MyAHSCoconnect flowsheet will automatically transfer to the Connect Care inpatient chart and is viewable on the *Glucose Management Accordion Report*, found in the summary activity. If the patient is unable to record their values in MyAHSCoconnect themselves, the health care provider is able to document patient reported readings on the *Inpatient Vital Signs flowsheet* activity under Point of Care Tests → Patient Reported Glucose row, which appears once the *MyChart IP Glucose Recording order* is placed. Refer to the *Inpatient Nurse - Glycemic Management Quick Start Guide* found on Insite or the Learning Home Dashboard.

For Connect Care sites, what do I scan to ensure the AHS BG meter result is accurately uploaded to the patient's chart?

Scan the **barcode** on the patient's wrist band, for more information see the Connect Care tip sheet *Patient Wristband Scanning*.

When should blood glucose (BG) testing occur?

Timing of Testing

- BG levels are to be tested four times daily, before each meal and before bedtime.
- Test BG if any suspicion of hypoglycemia.
- Ideally, testing needs to happen within 30 minutes of the patient's meal. Meal delivery times are unit specific.
- Patients that are fasting, have a continuous tube feed, or parenteral nutrition (PN) require testing at usual scheduled meal times and bedtime, or every six hours.
- When the patient will be off unit at a location where BG testing is not readily available, and/or the patient will be engaging in physical activity, the BG should be tested before the patient leaves the unit.

When should blood glucose (BG) test be repeated?

- When the result is inconsistent with patient's clinical status; or
- suspected equipment malfunctioning including expired test strips or visible changes to the test strip.

What is the recommended timing of insulin administration?

Coordination of blood glucose (BG) Testing and Insulin Administration

Both the BG test and insulin administration are to be coordinated with meal delivery and occur 15-30 minutes before the meal.

- Short acting insulin is given 30 minutes prior to mealtime
- Rapid acting insulin is given no more than 15 minutes prior to mealtime

Exception: meal/bolus insulin may be given immediately **after** the meal/feed in certain situations (e.g., gastroparesis or concern that the patient may not be able to ingest or retain the full meal).

What is Basal Bolus Insulin Therapy (BBIT)?

Basal Bolus Insulin Therapy (BBIT) is a way of ordering multiple daily injections of subcutaneous (sc) insulin that better replicates how our body naturally produces insulin.

BBIT allows clinicians to customize insulin regimes based on the unique needs of each patient. It is a proactive approach to managing blood glucose (BG) values and aims to anticipate a patient's insulin needs. A BBIT regime can minimize the risk of having high and low BG levels in hospital. Less fluctuation in BG values is better for the patient and the patient feels much better. BBIT has been shown to be an effective way to manage patients' diabetes during their hospital stay and is more similar to how patients manage their diabetes in the community.

BBIT includes three components: basal insulin (long acting), bolus (short acting or meal-time) insulin, and correction insulin.

Basal Insulin - covers the glucose the liver (and to a lesser extent the kidneys) makes around the clock

Bolus insulin - covers the mealtime carbohydrates

Insulin Correction - corrects the patient's BG back into target range if it is high

Titrate - Every patient is different! The BG is checked regularly and insulin doses adjusted every 1-3 days

For more information, please visit the BBIT website at: www.bbit.ca

What is meal insulin?

Meal/bolus insulin is given to cover the mealtime carbohydrates (the rise in blood glucose from eating). This is rapid or short acting insulin given prior to meals.

What is the difference between rapid acting insulin and short acting insulin?

Rapid acting insulin (e.g., lispro or aspart) are insulins with an onset of 10-20 minute, peak of 1-3 hours and a duration of 3-5 hours.

Short acting insulin (e.g., insulin regular) are insulin with an onset of 30-60 minutes, peak of 2-4 hours and a duration of 6-8 hours.

Refer to the *Insulin Action Comparison Chart* on the Insulin Safety & Diabetes Management page found on Insite.

When should insulin be held?

The meal/bolus insulin dose should be held if the patient is not receiving nutritional intake, nothing by mouth (NPO) or fasting for a test or procedure. (The basal insulin should be administered as prescribed, as well as the correction insulin if required, as per orders.)

If there is a change in the patient's oral intake (increased nausea and vomiting or decreased appetite), the prescriber needs to be contacted, as the insulin dose may or may not need to be adjusted.

Where do I find the guidelines for Safe Management of Insulin Pump Therapy (IPT) in hospital?

The Guidelines for the Safe Management of Insulin Pump Therapy in Hospital guideline HCS-174-01 can be found at www.ipumpit.ca. These guidelines support patients to self-manage with their insulin pumps when safe and appropriate. They also support the safe transition to another insulin regimen when patients are unable to self-manage using their insulin pump.

Key Message of guidelines- “If pump stopped, must replace basal insulin within 2 hours to prevent Diabetic Ketoacidosis (DKA)”

Hypoglycemia Procedure

Who does the hypoglycemia procedure apply to?

Treatment is for all appropriate patients with a blood glucose less than four (4.0) mmol/L, even those asymptomatic who meet the criteria below:

- Patients with diabetes or gestational diabetes, who are on at least one of the following medications: insulin or insulin secretagogues (e.g., glyburide, gliclazide, glimepiride or repaglinide).
- Patients without diabetes who have symptomatic hypoglycemia due to insulin or insulin secretagogue overdose (e.g., glyburide, gliclazide, glimepiride or repaglinide), malnutrition, liver failure, or more rare conditions (e.g. insulinoma, late dumping syndrome, etc.).

This hypoglycemia protocol should **not** be applied to:

- Patients with diabetes who are not taking insulin or insulin secretagogues (e.g., glyburide, gliclazide, glimepiride or repaglinide).
- Asymptomatic patients who do not have diabetes (since healthy people who are fasting can have blood glucose levels below four [4.0] mmol/L).

What are the signs and symptoms of hypoglycemia?

Early/non-severe symptoms: headache, mood changes, irritability, tremors, tiredness, tachycardia, excessive hunger, diaphoresis, pallor, paresthesia, and/or inability to concentrate. These are adrenergic/neurogenic responses.

Advanced/severe symptoms may include all of the early/non-severe symptoms as well as: being unable to recognize and treat hypoglycemia by self, disorientation, altered level of consciousness (including unconscious state), and/or seizure. These are neuroglycopenic responses.

The early/non-severe symptoms of hypoglycemia are usually followed by advanced or severe symptoms, if treatment does not happen in a timely fashion.

Why do some patients experience asymptomatic hypoglycemia or hypoglycemia unawareness?

Individuals with impaired glucose counter-regulatory responses to hypoglycemia may not experience early/non-severe symptoms prior to advanced/severe symptoms, even with low glucose levels. Glucose counter-regulation refers to the normal rise in glucagon, growth hormone, sympathetic (epinephrine, norepinephrine), and adrenal (cortisol) hormones in response to a low blood glucose, which counteracts the glucose-lowering effects of insulin and tends to increase blood glucose. Some medications such as beta blockers or sedatives can impair the glucose counter-regulation and increase the individual's risk for experiencing an asymptomatic hypoglycemia event. Mild and frequent episodes of hypoglycemia may also be a risk factor for asymptomatic hypoglycemia or hypoglycemia unawareness as it can reduce the normal glucose counter-regulation response to hypoglycemia.

Should the meal/bolus insulin be held if the patient's pre-meal blood glucose (BG) is less than 4.0mmol/L?

When the patient experiences hypoglycemia before a meal, the hypoglycemia should be treated (according to the hypoglycemia procedure) until their BG is greater than 4.0 mmol/L. The patient should then receive their meal insulin if they are eating their meal.

When should 15 grams carbohydrate be given orally to a patient?

- When blood glucose (BG) is less than 4.0 mmol/L **and** the patient is considered appropriate for this procedure, see FAQ page 15.
- For patients requiring thickened fluids: provide thickened juice based on the thickness indicated in the patient's diet order.
- Patients on acarbose (Glucobay): **only** dextrose (glucose) tabs or honey may be used as the medication delays the absorption of sucrose.

*Patients who are NPO or have an altered level of consciousness should not receive the carbohydrate by mouth.

What are some examples of 15 grams of carbohydrate that can be given orally?

- 4 glucose tablets* (16 g of carbohydrate); or
- 175 mL or three-quarter (3/4) cup of juice or regular pop; or
- 1 and ½ individual packages (or 15 mL or 18 g of carbohydrate) of honey; or
- 4 packets of sugar (white or brown), dissolved in water.

*Glucose tablets are the **preferred treatment** for hypoglycemia. Other options may not be readily available in AHS facilities, as this is unit and site dependent.

*Glucose tablets are the preferred treatment for hypoglycemia in patients who have had bariatric surgery. Due to anatomical changes of bariatric surgery other treatment options may not be tolerated.

*Glucose tablets may be crushed and dissolved in water.

When a conscious patient has a tube feed, how do I treat the hypoglycemia?

If the patient has a tube feed and unable to have nutritional intake by mouth, provide four glucose tablets crushed and dissolved in water via tube feed **AND** flush with 30mL water (pre and post treatment).

Juice, pop and honey are not acceptable treatment options as they may cause clogging or damage to the tube.

If the patient is NPO or has an altered level of consciousness, follow the treatment recommendations outlined in the AHS procedure treatment of hypoglycemia.

Where do I find information on alternate/replacement food menu items when the food or menu item recommended in the procedure is not available on my unit or not appropriate for the patient?

If none of the recommended options are available or appropriate for the patient, discuss the best options with the dietitian.

What is a schedule 1 medication?

A Schedule 1 medication is a medication that requires a prescription or order from an authorized prescriber. Controlled drugs and substances are included in Schedule 1. For information on medication schedules please see the Scheduled Drugs Regulation under the Pharmacy and Drug Act (2000).

Can nurses (RN, RPN, LPN) give D50W without a prescriber's order?

In emergent situations where it is not possible to obtain an order prior to initiating a protocol, contacting the MRHP can happen at the same time as the protocol and interventions within it are being implemented. Confirm the dose of the medication with MRHP before administration, when possible.

Dextrose IV solutions including D50W IV direct are schedule 1 medications, these are medications that requires an order or prescription. Refer to the dextrose product monograph in the provincial parenteral manual on Insite for more information.

College of Registered Nurses of Alberta (CRNA) Medication Guideline 10: *Nurses must have a client specific order from an authorized prescriber in order to implement a **protocol** that includes the administering of Schedule 1 medications within the named protocol.*

College of Licensed Practical Nurses of Alberta (CLPNA) Medication Guideline Protocols: A **protocol** is an organizationally-approved guide for practice that is to be implemented by health care professionals managing specific client health needs in their practice environment.

Emergent situations are defined (in the CRNA document) as circumstances that call for immediate action or attention such that a delay in treatment would place an individual at risk of serious harm.

What if nurses on our unit are not competent and confident to administer IV direct medications?

If the nurse or MRHP treating the patient who is experiencing hypoglycemia with an altered level of consciousness is not competent and confident to provide IV direct medication, IV D50W shall be administered in a minibag (following the D50W monograph) as per the procedure and algorithm.

Why is a large vein required for the administration of D50W?

IV D50W is a hyperosmolar solution. It should only be administered IV direct via a large vein (e.g., antecubital). Administered into a small vein, it can cause extravasation and consequential complications including tissue injury and loss of limb.

Can I give D50W IV after I administer glucagon (inhaled) if an IV is established or do I wait for 15 minutes?

Glucagon is to be administered in the patient that is unable to swallow or has an altered level of consciousness, **when IV access is not available**. Once IV access is established, D50W IV is to be administered as D50W action time is significantly quicker than glucagon.

The BG will be re-assessed 15 minutes after the D50W is administered.

Where can I find information on how to administer glucagon?

Instructions for administering glucagon can be found in the glucagon medication package (instruction insert) as well as on the Insulin Safety & Diabetes Management page found on Insite

Why is there a switch from subcutaneously or intramuscularly (SC or IM) glucagon to intranasal glucagon on the formulary?

Glucagon (Baqsimi®) nasal powder 3 mg has been added to the AHS Provincial Drug Formulary and Correctional Facilities Drug Formulary Supplement, **formulary restricted (FR): for the treatment of severe hypoglycemia in patients four years and older without IV access and impaired level of consciousness, and unable to take oral carbohydrates.** The previous product, Glucagon 1 mg injection manufactured by Eli Lilly and Paladin is discontinued, with no current parenteral glucagon injectable alternative marketed in Canada.

Do I need an order to administer glucagon in an emergent situation?

Yes, glucagon is schedule 2 medication, these are medications that requires an order for administration in the acute care setting as per AHS Medication Management Policies found on Insite.

What do I do for patients with a blood glucose (BG) between 4.0 - 5.0 mmol/L?

- The target BG for most hospitalized patients with diabetes is 5.0-10.0 mmol/L.
- Treatment of hypoglycemia is initiated when the BG is less than 4.0 mmol/L.

A BG between 4.0-5.0 mmol/L in the hospital setting does not require intervention **unless the patient is symptomatic of hypoglycemia**. If the patient is experiencing symptoms of hypoglycemia the hypoglycemia procedure is to be followed.

A patient with a BG between 4.0-5.0 mmol/L, should be assessed for symptoms of hypoglycemia prior to being sent off the unit for a test, procedure, physical activity, etc., and communication between departments should occur.

Frequent BG values between 4.0-5.0 mmol/L with symptoms of hypoglycemia may require titration of medications for diabetes management.

Why shouldn't the patient be sent off the unit when their blood glucose (BG) is less than 4.0mmol/L?

When the BG is less than 4.0 mmol/L, the patient may feel unwell.

Symptoms of hypoglycemia include: Excessive hunger, Nausea, Irritability, Tachycardia, Mood changes, Diaphoresis, Tiredness, Tremors/trembling, Inability to concentrate, Headache, Confusion

When patients take insulin or oral insulin secretagogues (e.g., glyburide, gliclazide, glimepiride or repaglinide), these medications will continue to lower blood glucose values if not treated appropriately. If a low BG is not treated the patient can develop an altered level of consciousness or have convulsions.

What is the rationale for re-assessing the blood glucose (BG) one hour after treatment of hypoglycemia?

Reassessing a BG level one hour after initial treatment is a safety measure. It is recognized that recurrent hypoglycemia may impair the patient's ability to sense subsequent hypoglycemia.

The hypoglycemia procedure is very lengthy. How can nurses respond in a timely manner in a crisis situation?

This 11-page governance document is summarized in a two-page algorithm, which is included as an appendix.

To support staff education there is an AHS video for Treatment of Hypoglycemia:
<https://www.youtube.com/watch?v=nljiyN8gGdU>

How can I document the elements of the hypoglycemia procedure in a timely fashion?

In Connect Care, nurses can access the nursing/allied health orders for the treatment of hypoglycemia. These orders can be started by nursing and co-signs requested as required. All elements of the procedures are included in the order panel.

Hyperglycemia Procedure

Why shouldn't the patient with diabetes be sent off the unit if their blood glucose (BG) is greater than 18.0mmol/L?

When BG levels are significantly elevated the patient may feel unwell. BG levels will continue to rise if untreated. High BG can put the patient at risk for the development of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) which are medical emergencies for patients with diabetes.

What is Diabetic Ketoacidosis (DKA)?

Diabetic ketoacidosis (DKA) is a diabetes emergency. It is caused by a deficiency of insulin in patients with Type 1 diabetes (autoimmune) or Type 3c (pancreatectomy, etc.) and those with Type 2 diabetes that are insulin deficient. The ensuing hyperglycemia results in a combination of osmotic diuresis (urinary water loss) and electrolyte abnormalities with resultant dehydration. Insulin deficiency and elevated glucagon levels lead to the breakdown of fat, producing ketones/acids. Ketones are an alternate energy source used when glucose is not available. High levels of ketones can lead to a life-threatening condition known as diabetic ketoacidosis (DKA).

The clinical presentation of DKA includes symptoms of hyperglycemia (see above), nausea, vomiting and abdominal pain, Kussmaul respiration (deep/laboured), acetone-odoured breath (sweet/fruity breath) and ECFV (extra cellular fluid volume) contraction (dehydration). There also may be a decreased level of consciousness. DKA is associated with significant morbidity and mortality and so should be prevented whenever possible.

Some patients may experience euglycemia DKA. Euglycemic DKA is a diagnosis of DKA, however the BG value is not as significantly elevated as anticipated. The glucose value may be within a normal range or only mildly elevated. Patients who take SGLT2i medications or pregnant patients with pre-existing Type 1 or Type 3c diabetes may experience euglycemic DKA. It is important to screen these patients for DKA with ketone testing when they are feeling unwell, regardless of glucose value.

What is Hyperosmolar Hyperglycemic State (HHS)?

Hyperosmolar Hyperglycemic State (HHS) is a diabetes emergency. It is caused by a relative deficiency of insulin in patients Type 2 diabetes **without** ketosis. Typically, an acute illness or infection precipitates the release of counter-regulatory hormones resulting in hyperglycemia. The ensuing hyperglycemia results in a combination of osmotic diuresis (urinary water loss) and electrolyte abnormalities with resultant dehydration. The clinical presentation of HHS includes symptoms of hyperglycemia (see above) and ECFV (extra cellular fluid volume) contraction (dehydration). Fever and focal neurological signs (e.g., decreased level of consciousness) are common signs of HHS. HHS is associated with significant morbidity and mortality and so should be prevented whenever possible.

How are ketones tested?

The patient's urine or blood serum can be tested for ketones. If patient has Type 1 or Type 3c diabetes and blood glucose is greater than 18.0mmol/L, stat ketone testing is recommended (to be ordered by the MRHP). Available method of ketone testing varies across acute care sites and will be site dependent.

Exception: Stat ketone testing is recommended if BG greater than 14.0mmol/l for

- a. Patients on insulin pump therapy
- b. Patients on sodium-glucose co-transporter 2 (SGLT2) inhibitors
- c. Pregnant patients with pre-existing Type 1 or Type 3c diabetes with symptoms of DKA, regardless of glucose value
 - a. DKA occurs in up to 3 per cent of pregnancies and carries maternal and fetal morbidity and mortality risk; 10-35 per cent of DKA in pregnancy results in fetal demise

What are SGLT2 inhibitor medications?

SGLT2 inhibitors (Sodium-glucose co-transporter two inhibitors) are oral medications to decrease blood glucose levels by increasing the amount of glucose passed through the urine.

The following medications are SGLT2 inhibitors: canagliflozin (Invokana®)*, dapagliflozin (Forxiga®), empagliflozin (Jardiance®)*

a. Are SGLT2 inhibitors on the AHS formulary?

SGLT2i medications with a * are formulary restricted medications. The other SGLT2i medications are nonformulary.

b. Are there any special considerations with SGLT2 inhibitors?

These agents may cause euglycemic DKA; in some cases, DKA has occurred in patients with normal or modestly elevated blood glucose. These medications may be held by the MRHP prior to events that may predispose the patient to DKA.

Where can nurses find a quick reference for treatment and management of hyperglycemia?

See algorithm attached to the hyperglycemia procedure.

General Information

What is the difference between Type 1, Type 3c and Type 2 diabetes?

Type 1 Diabetes Mellitus (T1DM)

T1DM is caused by destruction of the insulin producing beta cells in the Islets of Langerhans, most commonly from an autoimmune process. The pancreas therefore produces very little or no insulin, so blood glucose (BG) rises (hyperglycemia). If the body cannot use glucose as an energy source, because of a lack of insulin, it breaks down fat and produces ketones, which are acidic. High levels of ketones can lead to a life threatening condition known as diabetic ketoacidosis (DKA).

People with T1DM need insulin therapy to survive, typically a basal bolus insulin regimen (may also be referred to as multiple daily injections). They tend to be less insulin resistant (require lower total daily doses [TDD] of insulin) and have a higher risk of developing severe hypoglycemia (the beta cells can no longer work in conjunction with the alpha cells that produce Glucagon).

People who live with T1DM are taught to carefully monitor their diet (carbohydrate intake), exercise and BG levels, and to administer insulin to help manage their BG levels at home.

Type 3c Diabetes Mellitus (Type 3c)

Type 3c diabetes also known as pancreatogenic diabetes, occurs when the pancreas is damaged (i.e. chronic pancreatitis or cystic fibrosis) or resected (pancreatectomy) and produces less of all the hormones produced by the pancreas, which includes insulin and glucagon. Similar to type 1 diabetes, people living with type 3c diabetes are at risk of developing severe hypoglycemia and DKA.

Type 2 Diabetes Mellitus (T2DM)

T2DM is a progressive chronic disease, with varying degrees of insulin resistance and insulin deficiency. The pancreas produces some insulin, but the cells in the body fail to respond to the insulin properly (insulin resistance). The pancreas often cannot produce

enough insulin to overcome this resistance without treatment. However, the pancreas is usually still able to make glucagon in response to insulin production, lowering the risk of severe hypoglycemia.

Initially when individuals are diagnosed with T2DM, diet and exercise lifestyle modifications are an important part of their long-term treatment. There are now many medications (oral, non-insulin injections and insulin) to help treat T2DM. Some medications reduce insulin resistance, others increase insulin production, others reduce glucagon and still others increase glucose loss in the urine. People living with T2DM for a long period of time will often need supplemental insulin therapy.

Summary:

Type 1 Diabetes (T1DM)

- Autoimmune in nature; the pancreas produces very little to no insulin
- These patients always require basal insulin
- At risk for diabetic ketoacidosis (DKA)
- At significant risk for hypoglycemia

Type 3c Diabetes (Type 3c)

- Also known as pancreatogenic diabetes (damage to the pancreas from pancreatic disease or a pancreatectomy)
- The pancreas produces very little to no insulin
- At risk for diabetic ketoacidosis (DKA)
- At significant risk for hypoglycemia

Type 2 Diabetes (T2 DM)

- A combination of insulin resistance and insulin deficiency
- The pancreas produces some insulin, but the body is resistant to its own insulin production
- Most patients will benefit from insulin supplementation in hospital

For more information; please visit [Diabetes Canada](#).

In what aspects are the management of Type 1, Type 3c and Type 2 diabetes similar?

The management of T1DM, T3c or T2DM in the hospital can be similar if a patient requires insulin to manage their blood glucose levels. A patient with T1DM will ALWAYS require insulin. A patient with T3c will often require insulin. A patient with T2DM may benefit from insulin in the hospital. When subcutaneous insulin is ordered and administered in the hospital, basal bolus insulin therapy (BBIT) is the recommended best practice as it closely mimics how the body naturally produces insulin.

Where can I find additional resources supporting improved glycemic management in hospital?

- a. Glycemic Management Policy resource page:
 - Video for hypoglycemia management education
 - Recorded webinar
 - Patient handout: Checking your blood glucose (sugar) level while you're in the hospital (alberta.ca)
- b. Insite: Insulin Safety & Diabetes Management
 - Insulin Safety & Diabetes Management
 - Search insulin or diabetes
- c. MyLearningLink
 - Search “Basic Diabetes” for an interactive learning module on basic diabetes education, with a focus on in-hospital diabetes management.
- d. Safer Practice Notices:
 - Safer Practice Notice- Safety Concerns regarding use of Home Glucose Monitoring Devices in Acute Care (albertahealthservices.ca)
- e. www.bbit.ca
 - PowerPoint presentations
 - Self-directed learning module
 - Posters
 - Pocket cards
- f. www.ipumpit.ca
 - Guidelines for Safe Management of Insulin Pump Therapy in hospital

2024 Revision Highlights

What are the updates to the policy and procedures in Fall 2024?

The following is a brief summary of the elements in the three governance documents that were revised, and the rationale for these revisions.

Glycemic Management – Adult Policy		
Section	Change	Rationale
Principles	<ul style="list-style-type: none">- term multidisciplinary changed to interdisciplinary and throughout all documents- type 3c diabetes was added everywhere type 1 diabetes was noted in all policy documents	<ul style="list-style-type: none">- better describes the team involved in glycemic management- type 3c diabetes also known as pancreatogenic diabetes, was added as a type of diabetes that should follow the same clinical care for glycemic management as people living type 1 diabetes
1.2 d (ii)	<ul style="list-style-type: none">- reference to a home glucose monitoring resource	<ul style="list-style-type: none">- developed since the last revision.
1.3 b	<ul style="list-style-type: none">- personal blood glucose changed to capillary blood glucose (CBG)- flash glucose monitors term removed	<ul style="list-style-type: none">- more descriptive term
3.1	<ul style="list-style-type: none">- new content added recommending that admitted patients (if not completed in the past year) have appropriate screening for hyperglycemia by ordering a glycated hemoglobin (A1C) or POCT fasting and/or random glucose if they meet any of following criteria: age 40 years and over, body mass index (BMI) equal to or greater than 25 kg/m², known history of diabetes mellitus (Type	<ul style="list-style-type: none">- aligns with Diabetes Canada clinical practice guideline criteria to identify patients who are at risk of hyperglycemia

	1, Type 2 or Gestational Diabetes Mellitus), and other risk factors as clinically indicated.	
3.4	- e.g., changed from steroid to glucocorticoids	- more descriptive term
3.9 b (iii)	- removed repetition and refer back to section 3.9 b(ii)	- remove repetition
3.9 (iv)	- added pregnant patients with type 1/type 3c diabetes with signs and symptoms of DKA regardless of glucose values	- these patients are recommended for stat ketone testing
3.11	- added content that health care professionals support patient access to diabetic diet	- support to MRHP
3.12	- added pregnant patients with type 1/type 3c diabetes with positive ketones, regardless of glucose values	- these patients should not be sent off unit for physical activity
References	- added perioperative management and home glucose monitoring resources to list	- developed since the last revision

Treatment of Hypoglycemia – Adult Procedure		
Section	Change	Rationale
1.3 a (i)	- content added to 1.3 a to clarify who the hypoglycemic protocol should not be applied to (i) <u>unless they have symptomatic hypoglycemia with a low blood glucose value</u>	- to provide more clarity and the inclusion criteria
1.4 & 5.2a)	-clarification that all medications need an order including dextrose solutions and glucagon	- the medication administration policy requires this not just for schedule 1 medications.

3.2	- content added explaining asymptomatic hypoglycemia – may occur in patients treated with medications that mask symptoms of low glucose (i.e. beta blocker, or sedatives) or in patients who have had recurrent low glucose events causing hypoglycemia-unawareness and those with cognitive impairment or reduced LOC.	- to provide more context/education for conditions where hypoglycemia may occur asymptomatic.
4.4 a) and throughout documents	- Dextrose tabs changed to Glucose tablets throughout documents	- this is the name currently supplied rather than Dextrose tabs and to reduce confusion
4.4 c) and throughout documents	- D5W changed to D10W for infusions	- this change matches Connect Care order sets and protocol and reflects best practice
3.5 b and throughout documents	- snack options (and amounts in grams) updated	- these changes match current recommended snack options available in AHS for hypoglycemia
5.4 a) & 5.7 d)	- added content about administering intranasal glucagon as preferred route	- this is for patient safety and will reflect AHS formulary changes
References	- added home glucose monitors resource	- this resource was developed since last revision
Appendix A	- updated hypoglycemia adult algorithm to match content changes in procedure	- promotes consistency as this algorithm is used frequently to support interventions

Treatment of Hyperglycemia – Adult Procedure		
Section	Change	Rationale
1.5 4.5 & 4.6	- content added to explain hyperosmolar hyperglycemic state (HHS) that can present with type 2 diabetes and has features that overlap with DKA. HHS is added to other sections in the hyperglycemia procedure where relevant	- to emphasize that HHS is an emergency situation and provide more guidance for assessment and interventions
1.6 d	- content added pregnant patient with type 1/type 3c diabetes and positive ketones, regardless of glucose value should not be sent off the unit for physical activity	- this was a treatment of hyperglycemia content gap for pregnant patients with diabetes
1.11 c	- content added to emphasize inaccuracy of capillary blood	- to emphasize importance of blood glucose testing verifying with clinical judgment
3.1 d	- content added about potential causes of hyperglycemia – medications associated with hyperglycemia (e.g. glucocorticoids)	- this is more education and provides a common drug in acute care settings that could lead to hyperglycemia
3.1 e	- content added about potential causes of hyperglycemia – acute illness or procedures that increase counterregulatory (stress) hormones (eg. infections, cardiac events, surgery)	- this is more education and provides other contexts when hyperglycemia could be identified
4.5 b	- content added about type of changes in vital signs to monitor for (e.g. hypotension, tachycardia, fever, altered mental status)	- this provides more guidance/education to health professional monitoring
6.1 b	- content added to document ketone results	- to promote consistency in documentation
Appendix A	Updated adult hyperglycemia algorithm to match content changes in procedure	- consistency as this algorithm is used frequently

Resources and References:

AHS Resources:

- 1.1 Diabetic Ketoacidosis, Adult – Emergency Department (DKA, Diabetes, Hyperglycemia, Hyperglycemic Hyperosmolar State) Clinical Knowledge Topic
- 1.2 Diabetic Ketoacidosis, Adult – Inpatient Clinical Knowledge Topic
- 1.3 Basal Bolus Insulin Therapy, Adult - Inpatient (BBIT) (ahsnet.ca) - Clinical Knowledge Topic
- 1.4 Guidelines for the Safe Management of Insulin Pump Therapy in Hospital
- 1.5 Insulin Safety and Diabetes Management (Insite- search insulin or diabetes)
- 1.6 AHS BBIT website (www.bbit.ca)
- 1.7 AHS IPUMPIT website (www.ipumpit.ca)
- 1.8 Treatment of Hypoglycemia in hospital Video: Treatment of Hypoglycemia

Non-Alberta Health Services Documents:

- 2.1 Checking your blood glucose (sugar) level while you're in the hospital. Patient Handout <https://myhealth.alberta.ca/Alberta/Pages/blood-glucose-hospital.aspx>
- 2.2 Medication Guidelines 2019 (College and Association of Registered Nurses of Alberta [CARNA])
- 2.3 Medication Guidelines 2018 (College of Licensed Practical Nurses of Alberta [CLPNA])
- 2.4 Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1-S325.
- 2.5 Umpierrez GE, Smiley D, Zisman A, et al. Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes. Diabetes Care. 2007; 30:2181-2186.
- 2.6 Galloway, J. A., R. E. Chance, K. S. E. Su: Human insulin and its modifications. In The Clinical Pharmacology of Biotechnology Products. Reidenberg M. M., ed. Amsterdam, Elsevier (1991), pp. 23-34
- 2.7 White JR, Campbell RK, Hirsch I. Postgraduate Medicine. June 2003; 113(6): 30-36

Appendix A: Glycemic Management - Adult Policy Working Group

Kathy Dmytruk (co-lead)	Senior Consultant, Medicine Program Improvement & Integration Network, Acute Care Alberta	Provincial
Tara MacEachern (co-lead)	Senior Advisor, Corporate Policy Services	Provincial
Joanna Law	Senior Practice Consultant, HPSP	Provincial
Betty Lazor	Pharmacist, Drug Utilization Committee	Provincial
Laura Harrison Smith	Medication Safety Nurse, Provincial Pharmacy Med Safety	Provincial
Rhonda Roedler	Practice Leader, Pharmacy	Provincial
Chantelle Smook	CNE - QEII Hospital	North
Dawn Kingham	CNE - Integrated Quality Management	Edmonton
Madie Anderson	CNE - Acute Inpatient, Alberta Hospital	Edmonton
Rae Popowich	CNE - Cardiac Sciences, RAH	Edmonton
Ifeyinwa Ezeuko	Inpatient Diabetes, UAH/KEC	Edmonton
Jennifer Goede	CNE - Learning Services, UAH/KEC	Edmonton
Sheila Hill	Head Nurse, RDRH	Central
Leanne Haines Doig	Practice Lead - Rural	Central
Brian Zarsky	Clinical Safety Leader, Patient Safety	Calgary
Stacey Lowrie	CNE, Day Surgery/FMC	Calgary
Jenn Watson	CNE, Unit 37 FMC (Renal)	Calgary
Lisa Jackson	CNE, Unit 74 RGH (Medicine)	Calgary
Shyann Rogan	CNE, PLC	Calgary
Sasha Wiens	Clinic Coordinator, Diabetes outpatient/inpatient	Calgary
Reema Gerlitz	CNE - Addictions and Mental Health, CRH	South
Linda Vogel	CNE - CRH	South
Kevin Walcer	Director, Medicine	South

Ad Hoc Members (Subject Matter Experts)

Dr. Julie McKeen	Medical Advisor, Endocrinologist	Calgary
Dr. Tammy McNab	Medical Advisor, Endocrinologist	Edmonton
Dr. Heather Paul	Medical Advisor, Pathologist	Provincial
Tracy Guttridge	Manager, APL POCT	Provincial
Sabrina Killen	RD, Nutrition Services	Provincial
Kim Young	RD, Nutrition Services	Provincial
Isabelle Emery	Patient Advisor	Calgary

Bev Madrick	Patient Advisor	Calgary
Danielle Denty	CNE- Surgery, NLRH	North
Darren McIlwaine	Practice Lead - Allied Health/Physio	Calgary

The co-chairs would like to thank the members of this working group for their time and expertise in the development of these documents.